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Efficient methods to functionalise proteins are essential for the development of many diagnostic 
and therapeutic compounds such as fluorescent probes for immunohistochemistry, zirconium-89 
radiolabelled monoclonal antibodies (89Zr-mAbs) for positron emission tomography (PET), and 
antibody-drug conjugates (ADCs). This protocol describes a step-by-step procedure for the light-
induced functionalisation of proteins with compounds bearing the photochemically active aryl 
azide (ArN3) group. As an illustration of the potential utility of our approach, this protocol focuses 
on the synthesis of 89Zr-mAbs using photoactivatable derivatives of the metal ion binding chelate 
desferrioxamine B (DFO). The light-induced synthesis of 89Zr-mAbs is a unique, one-pot process 
involving simultaneous radiolabelling and protein conjugation. The photoradiochemical synthesis 
of purified 89Zr-mAbs, starting from unmodified proteins, [89Zr][Zr(C2O4)4]4– (89Zr-oxalate), and 
a photoactivatable DFO derivative, can be performed in less than 90 minutes. The method can be 
easily adapted to prepare other radiolabelled proteins, ADCs or fluorescently-tagged proteins using 







Protein-based drugs and related biological products (biologics) represent one of the fastest growing 
sectors in the pharmaceutical industry. The versatile structure and function of proteins make them 
ideal scaffolds for designing sophisticated drugs that exhibit high affinity, target specificity, and 
optimised pharmacokinetics. Monoclonal antibodies (mAbs) and immunoglobulin fragments are 
frequently used as protein components in many biologics designed as therapeutic or diagnostic 
agents. For example, mAbs functionalised with fluorophores are used as biochemical tools in 
immunohistochemistry, fluorescence-assisted cell sorting or confocal fluorescence microscopy; 
antibody-drug conjugates (ADCs) are among the latest generation of targeted chemotherapeutics; 
and 89Zr (t1/2 = 78.41 h) radiolabelled mAbs are a cornerstone of diagnostic PET imaging in 
Nuclear Medicine.  
The synthesis of radiolabelled mAbs (and other protein-drug conjugates) requires chemical 
modification of the glycoprotein.1 Standard protein coupling chemistries rely almost exclusively 
on thermochemically induced reactions such as the post-translational modification of amino-acid 
side chains or the site-specific labelling of glycans by chemical or enzymatic methods.2–10 
Although highly successful, these classic approaches suffer from a number of important 
limitations. For instance, most existing methods are time consuming and difficult to automate. 
Chemical reagents used for conjugation to amine (-NH2), carboxylate (-CO2–), or sulfhydryl (-SH) 
groups frequently involve multiple step syntheses and are incompatible with protein formulation 
buffers which contain various redox stabilisers, amino acids, sugars and other solubilising agents. 
As an example, an outstanding Nature Protocol by Vosjan et al.11 describes the two-step protein 
conjugation and radiosynthesis of 89Zr-mAbs using p-isothiocyanatobenzyl-desferrioxamine B 




and available primary amines on the protein (mainly the e-NH2 side-chain of lysine) at pH 9. DFO-
Bn-NCS conjugation to mAbs is highly reproducible with conjugation efficiencies of 60% to 80%. 
However, the reaction conditions do not tolerate the presence of free amino acids. Hence, pre-
purification of the mAb from other formulation components is necessary for functionalisation 
using Bn-NCS chemistry. Standard thermochemical routes also require the isolation, 
characterisation, and storage of an intermediate new molecular entity (the conjugated mAb), which 
poses both practical and economic problems during clinical translation.  
 
Development and Overview of the Protocol 
An ideal method for protein-conjugation should be a simple, fast and reproducible process 
that can be performed in a single step under mild conditions using well-characterised, stable 
precursors. In 2019, our group demonstrated that light-induced activation of chelates bearing aryl 
azide (ArN3) groups and radiolabelled with a variety of different radionuclides, including 68Ga3+ 
and 89Zr4+ ions, can produce viable PET radiotracers direct from formulated antibody solutions.13–
20 The underlying concept of bimolecular photochemically induced protein modification is shown 
in Figure 1.19,21  
The key motivation for developing an alternative protein conjugation and radiolabelling 
strategy was to eliminate steps that involved pre-purification of the protein and isolation of a 
functionalised (non-radiolabelled) intermediate molecule. The functionalised intermediates that 
are produced from existing methodologies can be categorised as New Molecular Entities (NMEs) 
and in some jurisdictions are subject to stringent absorption, distribution, metabolism excretion 
and toxicological (ADME-tox) testing. Aside from the very high economic costs, obtaining 




logistical challenge that prohibits many smaller research groups and facilities from developing 
89Zr-mAbs.  
By minimising the number of steps, reducing reaction times, and by performing the 
bioconjugation chemistry in the presence of standard formulation buffers, we were able to reduce 
the risk of compromising the integrity of the sensitive biological materials (antibodies and other 
proteins). Photochemical methods provide access to a unique set of covalent linkages (here the 
ArN3 produces a heterocyclic azepin group) which offers new opportunities for designing protein-
conjugates with advanced functionality for controlled drug release. 
 
Advantages and Limitations 
Our recent experiments have shown that a photoradiosynthetic approach to produce 89Zr-
mAbs from ArN3-based reagents has several advantages over existing methods. These include: i) 
rapid reaction kinetics – the protein conjugation and radiolabelling steps occur simultaneously, 
under the same conditions, and the entire one-pot reaction is performed in <15 min; ii) the 
photochemical conjugation process is tolerant to water, oxygen, salts and clinical-grade mAb 
formulation buffers that can include high concentrations of free amino acids (such as histidine), 
sugars and surfactants (such as polysorbate 20); iii) photoactivation occurs at wavelengths (365 – 
395 nm) where antibodies do not absorb; and iv) 89Zr-mAbs can be synthesised directly from 
formulated stocks avoiding pre-purification of the protein and isolation of intermediates; others 
have made important progress on automated methods for producing 89Zr-mAbs,22 yet the chemistry 
still requires the use of pre-functionalised intermediates. In contrast, the photoradiochemical 




In spite of the many attractive features, photochemical synthesis of protein-conjugates 
involves several limitations that are distinct from standard thermochemical processes. The light-
induced chemistry is highly dependent on the experimental geometry. Kinetic studies have shown 
that for compounds bearing an ArN3 group, the photo-initiation step is highly efficient and linearly 
dependent on photon flux. However, quantum yields for photochemical activation depend on the 
photon beam shape, focal point, and reaction volume. Scattering or absorption of the incident light 
by the reaction vessel or chemical components in the mixture can also have a dramatic impact on 
the observed conjugation yields. Experimentally, radiochemical yields (RCYs) of 68Ga- or 89Zr-
mAbs have also shown a steep dependence on pH and the initial protein concentration.13,15,18,20 
This protocol introduces the procedure for performing simultaneous, one-pot photoradiolabelling 
of 89Zr-mAbs and some of the considerations that must be taken into account when performing 
photochemistry in the context of protein conjugation. 
 
Applications 
The primary application envisaged for this protocol is the synthesis of radiolabelled proteins, and 
in particular 89Zr-mAbs, for use in diagnostic and nuclear medicine procedures. In recent work, 
we demonstrated that photoradiochemistry can also be used with different radioactive metal ions 
(published: 68Ga, 89Zr, 111In; unpublished: 64Cu, 99mTc, 177Lu), metal binding chelates (DFO, 
NOTA, NODAGA, DOTA, DOTAGA, DTPA, HBED-CC), and proteins including serum proteins 
like human serum albumin (HSA), immunoglobulins (IgG1: trastuzumab; HerceptinTM), and 
engineering protein constructs (scFv-Fc fragments including onartuzumab; MetMAbTM).13–19 




We note that the chemistry is not limited to the production of radioactive materials. Our 
recent work on the development of photoactivatable fluorophores (PhotoTags) demonstrated that 
protein functionalisation with BODIPY-ArN3 can be achieved by using a similar protocol.21 In 
addition, we are actively working on the synthesis of ADCs using photochemical methods to link 
cytotoxic payloads to a variety of biochemical vectors. 
 
Experimental Design 
As an example, this protocol describes the one-pot photoradiosynthesis of [89Zr]ZrDFO-PEG3-
azepin-onartuzumab.20 Prior to commencing work, it is important have access to a suitable 
photoactivatable chelate. Details of the chemical synthesis and characterisation of DFO-PEG3-
ArN3 (1) are provided in Box 1. Further details on the synthesis and characterisation of other 
photoactivable chelates, including compounds 2 and 3, are reported elsewhere (Figure 2).13–20 We 
note that during the development of this protocol, variations in radiochemical yields (RCY) were 
obtained. The most important factors that influence the final RCY include the nature of the protein 
undergoing functionalisation, the composition of the formulation, and particularly the protein 
concentration in the reaction mixture.18 Optimisation is likely required for each independent 
protein to obtain the maximum protein conjugation efficiency and highest RCYs. Furthermore, the 
experimental geometry has a major influence on the success and reproducibility of the procedure. 
Prior to using the protocol to synthesise 89Zr-mAbs, optimisation of the experimental set-up should 
be performed to ensure maximum delivery of the light into the reaction mixture. Dedicated 
photochemical reactors exist but to facilitate the use of the protocol, the chemistry was performed 
by using a simple experimental design that is accessible to standard chemistry and radiochemistry 




BOX 1 – Synthesis and Characterisation of DFO-PEG3-ArN3 (1) • TIMING 6 days 
This box describes the synthesis of photoactivatable DFO-PEG3-ArN3 (1) according to the 
schematic shown below (adapted from Ref. 20). 
 




CRITICAL: All reagents purchased from commercial sources were used without further 
purification. 
- 4,7,10-Trioxa-1,13-tridecanediamine (CAS no. 4246-51-9; Merck, cat. no. 369519)… 
- di-tert-butyl dicarbonate (Boc2O, CAS no. 24424-99-5; Merck, cat. no. 361941) 
- 4-azidobenzoic acid (CAS: 6427-66-3, Merck, cat. no. 778877) 
- 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate, (HATU, CAS: 148893-10-1, Merck cat. no. 11373) 
- N,N-diisopropylethylamine (DIPEA, CAS: 7087-68-5, Merck, cat. no. D125806) 
- MgSO4 (CAS: 7487-88-9, Merck, cat. no. M7506) 
- Trifluoroacetic acid (CAS: 76-05-1, Merck, cat. no. T6508) 
- NaHCO3 (CAS: 144-55-8, Merck, cat. no. S8875) 
- Succinic anhydride (CAS: 108-30-5, Merck, cat. no. 239690). 






CRITICAL The syntheses of intermediate compounds 4, 6, 7 and 8 are adapted from Patra et al., 
Angew. Chemie Int. Ed., 58, 1928–1933 (2019). DOI: 10.1002/anie.201813287.13  
1. Synthesize compound 4 (tert-butyl 3-(2-(2-(3-
aminopropoxy)ethoxy)ethoxy)propylcarbamate) by following the procedure reported by 
Liu et al.23 Briefly, a solution of 4,7,10-Trioxa-1,13-tridecanediamine in CH2Cl2 and di-
tert-butyl dicarbonate in CH2Cl2 was reacted overnight under Ar(g). The mixture was 
concentrated under reduced pressure, washed with sat. NaHCO3, and dried over MgSO4.  
2. Synthesize compound 6 (tert-butyl (1-(4-azidophenyl)-1-oxo-6,9,12-trioxa-2-
azapentadecan-15-yl)carbamate) by reacting a stirred solution of 4-azidobenzoic acid 
(compound 5, 1.0 g, 6.13 mmol) and 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate, (HATU,  3.5 g, 9.2 mmol) in dry 
dimethylformamide (DMF, 8 mL) with N,N-diisopropylethylamine (DIPEA, 3.16 g, 24.6 
mmol). After 40 minutes stirring at 23 oC under N2 atmosphere, add compound 4 (3.93 g, 
12.3 mmol) dropwise in DMF (4 mL) and stir the mixture for 24 h. Monitor the reaction 
by TLC (silica gel, EtOAc). Remove the solvent under reduced pressure and dissolve the 
residue in CH2Cl2 (150 mL). Wash the organic layer with H2O (3 ´ 100 mL) and brine (2 
´ 100 mL). Dry the residue over MgSO4, followed by filtration and removal of the solvent 
under reduced pressure. Purify the crude sample by column chromatography (silica, 
EtOAc) to give compound 6 as a slightly yellow oil (2.43 g, 88%). Characterisation data 
including 1H- and 13C{1H}-NMR spectroscopy, high-resolution electrospray ionisation 
mass spectrometry (HRMS) and reverse-phase high-performance liquid chromatography 




3. Deprotect compound 6 by dissolving compound 6 (1.30 g, 2.79 mmol) in CH2Cl2 (5 mL), 
add trifluoroacetic acid (3 mL) at 0 °C, and then stir the mixture overnight. Wash the 
organic layer with sat. NaHCO3(aq) (3 ´ 30 mL; powdered form of NaHCO3(s), dry over 
MgSO4 and remove the solvent under reduced pressure to give compound 7 as a yellow oil 
(1.01 g, 99%). Characterisation data including 1H- and 13C{1H}-NMR spectroscopy, high-
resolution electrospray ionisation mass spectrometry (HRMS) and reverse-phase high-
performance liquid chromatography (HPLC) are reported elsewhere.13,20 
4. Synthesize compound 8 by reacting a stirred solution of compound 7 (348 mg, 0.952 mmol) 
in DMF (5 mL) with succinic anhydride (143 mg, 1.43 mmol). Stir the mixture for 48 h at 
room temperature under an atmosphere of N2. After evaporation of the solvent, purify the 
crude product by flash chromatography (C18, H2O to H2O/MeOH 5/95) to give compound 
8 as a yellow oil (290 mg, 66%). Characterisation data including 1H- and 13C{1H}-NMR 
spectroscopy, high-resolution electrospray ionisation mass spectrometry (HRMS) and 
reverse-phase high-performance liquid chromatography (HPLC) are reported 
elsewhere.13,20 
5. Synthesize the photoactivatable compound DFO-PEG3-ArN3 (compound 1) by standard 
amide bond formation: First, dissolve compound 8 (690 mg, 1.48 mmol) and HATU (844 
mg, 2.22 mmol) in DMF (100 mL). Then, add DIPEA (1.03 mL, 5.92 mmol) and stir the 
mixture for 45 min at room temperature, followed by the addition of DFO mesylate (1.17 
g, 1.78 mmol). Stir the mixture for 48 h before evaporation of the solvent under reduced 
pressure. Purify the crude product by flash chromatography (C18, 135 g, H2O to 




solvent under reduced pressure. Obtain a purified sample of the product by dialysis and 
lyophilisation to give compound 1 as a pale-yellow amorphous powder (1.02 g, 69%).  
CRITICAL STEP: Analytical Data for compound 1: 1H NMR (DMSO-d6, 400 MHz, 298 
K) δ (ppm) 1.04-1.34 (m, 6H, CH2), 1.37-1.40 (m, 4H, CH2), 1.48-1.51 (m, 4H, CH2), 1.57-
1.62 (m, 2H, CH2), 3.0-3.12 (m, 6H, CH2), 3.30-3.57 (m, 20H, CH2), 7.19 (d, 2H, 3J = 8 
Hz, CHAr), 7.76 (br s, 3H, N-OH), 7.88 (d, 2H, 3J = 8 Hz, CHAr), 8.44 (br s, 1H, NH), 9.66 
(br s, 2H, NH). 13C{1H} NMR (DMSO-d6, 101 MHz, 298 K) δ (ppm) 20.78 (CH3), 23.9 
(CH2), 26.5 (CH2), 28.0 (CH2), 29.3 (CH2), 29.8 (CH2), 30.4 (CH2), 31.3 (CH2), 31.4 (CH2), 
36.3 (CH2), 37.2 (CH2), 38.7 (CH2), 38.9 (CH2), 47.2 (CH2), 47.5 (CH2), 68.5, 68.7, 70.0, 
70.0, 70.2, 70.3 (CH2 PEG), 119.3 (CHAr), 129.5 (CHAr), 131.6 (Cqt), 142.6 (Cqt), 165.7 
(C=O), 171.6 (C=O), 171.7 (C=O), 171.8 (C=O), 172.4 (C=O). HR-ESI-MS m/z calcd. 
for [C60H75N6O8+2H]2+ 504.78960, found 504.78962. RP-HPLC (C18 analytical HTec 
Nucleodor Column, 254 nm): Rt = 8.82 min. Analytical RP-HPLC method: Nucleodur EC 
250/4, 4 mm ID ´ 250 mm (C18 HTec, 5 µm) at a flow rate of 1 mL min-1 with a gradient 
of A (distilled H2O containing 0.1% vol/vol TFA) and B (MeOH containing 0.1% vol/vol 
TFA): t = 0-2 min, 40% B; t = 2-9 min, 95% B; t = 11 min, 5% B. 
  PAUSE POINT Compound 1 can be stored in the dark at -80 oC for at least 3 months. 







• Antibody or protein stock solution (typically 0.1 – 10 mg total protein mass; at a stock 
protein concentration ³0.5 mM). CRITICAL: in our experiments with trastuzumab 
(formulated as HerceptinTM, Genentech, Inc., South San Francisco, United States of 
America) and onartuzumab (formulated as MetMAbTM, Genentech Inc.) we found that 
pre-purification of the antibody from the formulation buffer is unnecessary.13,15,18,20 
Commercially sourced stock solutions of MetMAbTM (typical protein concentration of 60 
mg mL-1) are formulated in 10 mmol L-1 histidine succinate, 106 mmol L-1 a,a-trehalose 
dihydrate, and 0.02% (vol/vol) polysorbate 20 at pH5.7.24 Stock solutions of HerceptinTM 
(typical protein concentration of >15 mg mL-1) were prepared by reconstitution of the 
Good Manufacturing Practise (GMP)-grade lyophilised powder in water. A standard vial 
of HerceptinTM contains trastuzumab (440 mg), L-histidine hydrochloride (9.9 mg), L-
histidine (6.4 mg), a,a-trehalose dihydrate (400 mg, a-D-glucopyranosyl-a-D-
glucopyranoside), and polysorbate 20 (1.8 mg). Stocks of HerceptinTM can be stored as 
lyophilised powders or as solutions at 4 oC for >1 year. Stock solutions of MetMAbTM can 
be aliquoted and stored at –20 oC for > 1 year.  
• Photoactivatable aryl azide compounds such as: DFO-PEG3-ArN3 (1) (C46H77N11O14; 
molecular weight = 1,008.19 g mol-1); DFO-PEG3-EtArN3 (2) (C48H81N11O14; molecular 
weight = 1,036.24 g mol-1); DFO-ArN3 (3) (C32H51N9O9; molecular weight = 705.81 g 
mol-1). Structures of compounds 1–3 are presented in Figure 2. CRTICAL: Compounds 
1–3 are prepared synthetically, in-house. The synthesis of compound 1 is described in Box 




corresponding author. Synthetic details and full characterisation data for compounds 1–3, 
including 1H- and 13C{1H}-NMR spectroscopy, high-resolution electrospray ionisation 
mass spectrometry (HRMS-ESI), high-performance liquid chromatography, electronic 
absorption spectroscopy, photochemical reactivity, and concordant data on the metallation 
complexes with natural ZrCl4 or radioactive [89Zr][Zr(C2O4)4]4– have been reported 
elsewhere.15,18,20 Photoactivatable derivatives of DFO can be stored in the dark at –80 oC 
for at least 3 months. The chemical purity should be checked by HPLC prior to use. 
• Distilled, deionised water (Milli-Q; >18.2 M MΩ·cm at 25 oC) treated with Chelex® 100 
sodium form (50-100 mesh; dry) resin (CAS no. 11139-85-8; Sigma-Aldrich, cat. no. 
C7901). 
• Sodium carbonate: (Na2CO3×10H2O; molecular weight = 286.14 g mol-1; 99.999% trace 
metal basis; CAS no. 6132-02-1; Merck, cat. no. 577782; see REAGENT SETUP)) 
• Hydrochloric acid: (HCl; 37 wt%; 99.999% trace metal basis; molecular weight = 36.46 g 
mol-1; CAS no. 7647-01-0; Merck, cat. no. 339253; see REAGENT SETUP) 
• Phosphate buffered saline: (normal 1X PBS at pH7.4; prepared from a 10X stock solution 
by dilution with water; Merck, cat. no. P5493) 
• Diethylenetriaminepentaacetic acid: (DTPA; C14H23N3O10; molecular weight = 393.35 g 
mol-1; CAS no. 67-43-6; Merck, cat. no. D6518; see REAGENT SETUP) 
• HPLC eluents (reverse-phase): Distilled, deionised water (Milli-Q; >18.2 M MΩ·cm at 25 
oC) and methanol (HPLC grade, >=99.9%; CAS no. 67-56-1, cat. no. 34860) containing 
0.1% (vol/vol) trifluoroacetic acid (CF3COOH; molecular weight = 114.02 g mol-1; 99%; 




• ITLC eluents: Diethylenetriaminepentaacetic acid aqueous solution (50 mM; pH7.4): 
(DTPA; C14H23N3O10; molecular weight = 393.35 g mol-1; CAS no. 67-43-6; Merck, cat. 
no. D6518; see REAGENT SETUP) 
• [89Zr][Zr(C2O4)4]4– (89Zr-oxalate) in ~1.0 M oxalic acid: (Radioactivity was purchased 
from a commercial vendor: PerkinElmer, Boston, United States of America but samples 
were manufactured and distributed by the BV Cyclotron VU, Amsterdam, The 
Netherlands). ! CAUTION Zirconium-89 (t1/2 = 78.41 h, Emax(b+) = 902 keV, I(b+) = 
22.74%, Eg = 909.2 keV [I = 99.0%], 511.0 keV [I = 45.5%]) emits positrons and high-
energy gamma rays. All operations must be performed by qualified personnel in an 
approved facility and following safety guidelines set forth by the local authorities, and the 
Nuclear Regulatory Commission. Experimental manipulations should first be practised 
using non-radioactive samples and researchers should follow the ALARA (As Low As 
Reasonable Achievable) protocols to minimise exposure to ionising radiation. The use of 
all appropriate personal protective equipment including lab coats, shoes, gloves, plastic 
safety glasses and radiation dosimetry monitoring devices including whole body and 
finger ring detectors, as well as audible personal dose rate monitors and contamination 
monitors is mandatory when handling radioactive materials. ¨ CRITICAL The 89Zr-




• pH indicator strips: (Merck Millipore; variable ranges including pH 0–14 [cat. no. 




• Calibrated automatic pipettes and tips: (volume ranges: 20 – 200 µL for reagent aliquots; 
0.5 – 10 µL for analytical ITLC measurements) 
• Calibrated pH meter: (SevenCompact Advanced pH Meter; Mettler Toledo, Greifensee, 
Switzerland, cat. no. S210-Std-Kit) 
• Calibrated analytical balance: (XSR205DU, Mettler Toledo, Greifensee, Switzerland, cat. 
no. 30355396) 
• Transparent glass sample vials: (2.0 mL screw vials 12´32 mm, Wicom Germany GmbH, 
Heppenheim, Germany, cat. no. WIC 41155-SIL) 
• Microcentrifuge tubes: (1.5 mL; Eppendorf LoBind; Merck, cat. no. Z666505) 
• Falcon tubes: (50 mL, self-standing, polypropylene; Corning New York, United States of 
America, cat. no. 430921) 
• Magnetic stir bars: (PTFE Æ 3´8 mm; Semadi AG, Ostermundigen, Switzerland, cat. no. 
0244) 
• Retort stand and clamp 
• Magnetic stirring plate: (For example, IKA® RCT basic IKAMAG™ safety control; 
Merck, cat. no. Z645060; a stirring rate <1000 rpm to avoid aggregation of the protein) 
• Silica-gel impregnated on glass fibre instant thin-layer chromatography strips: (ITLC; 
Agilent Technologies, cat. no. SGI0001) 
• Geiger Counter: (Ranger EXP Geiger Counter with external pancake detector, Mineralab, 
New York, United States of America) 
• Calibrated activimeter (dose calibrator): ISOMED 2010 (Nuklear-Medizintechnik, 
Dresden, Germany) 




• HPLC systems with electronic absorption and radioactive detection (g or b+) connected in 
series. In our lab, analytical HPLC experiments on small-molecules and complexes are 
performed by using Hitachi Chromaster Ultra Rs systems fitted with a reverse phase VP 
250/4 Nucleodur C18 HTec (4 mm ID x 250 mm, 5μm) with electronic absorption 
measured at 220, 254 or 280 nm. Automated size-exclusion chromatography on protein 
samples is performed by using a Rigol HPLC system (Contrec AG, Dietikon, Switzerland) 
with electronic absorption measured at 280 nm. Both HPLC systems are connected to a 
radioactivity detector (FlowStar2 LB 514, Berthold Technologies, Zug, Switzerland) 
equipped with a 20 µL PET cell (MX-20-6, Berthold Technologies). 
• Size-exclusion chromatography gel filtration column: (ENrich SEC 70 or 650, 10 ± 2 µm, 
10 mm ID x 300 mm; Bio-Rad Laboratories, cat. no. 780-1070 or 780-1650, respectively) 
• Disposable PD-10 desalting columns for manual analytical and preparative size-exclusion 
chromatography: (Sephadex® G-25 resin, 85-260 µm, 14.5 mm ID x 50 mm, >30 kDa, 
GE Healthcare; Merck, cat. no. GE17-0851-01). CRITICAL: the loading/dead-volume of 
the PD-10 columns is precisely 2.50 mL which was discarded prior to aliquot collection. 
• Calibrated automatic gamma counter for accurate quantification of radioactivity: 
Experiments used a HIDEX Automatic Gamma Counter (Hidex AMG, Turku, Finland)  
• Light-emitting diodes with digital power control: Experiments used portable light-emitting 
diodes (LED; 365 nm or 395 nm) operated by a digital UV-LED controller (Opsytec Dr. 
Gröbel GmbH, Ettlingen, Germany). Spectroradiometric experiments confirmed that a 
setting of 100% corresponded to a power of approximately 263 mW at 365 nm and 355 




width at half-maximum [FWHM] = 9.1 nm). The LED (395 nm) had a maximum emission 
intensity at 389.9 nm (FWHM = 9.1 nm). (see Figure 4) 
 
REAGENT SETUP 
Sodium carbonate solution (1.0 M in water): Add 14.31 g Na2CO3×10H2O to a 50 mL Falcon 
tube and dissolve in water (50 mL). This solution can be stored at room temperature (23 ± 2 oC) 
for >1 year. 
 
Hydrochloric acid solution (0.1 M in water): First prepare a 5.0 M solution of HCl by adding 
20.53 mL HCl (37 wt %, d = 1.2 g mL-1 at 25 oC, [HCl] = 12.17 M) to a 50 mL Falcon tube 
containing 29.67 mL water. Prepare a 0.1 M HCl working stock by adding 1.0 mL 5.0 M HCl to a 
50 mL Falcon tube containing 49.0 mL water. This solution can be stored at room temperature for 
>1 year. ! CAUTION Acid dilution in water is highly exothermic. Allow the mixture to cool to 
ambient temperature before proceeding. 
 
ITLC eluent (50 mM DTPA at pH7.4): Add 0.983 g DTPA to a 50 mL Falcon tube and add 30 
mL water. Adjust the pH to 7.4 by adding aliquots of 1.0 M Na2CO3(aq.) solution and check the 
pH with a calibrated pH meter. Ensure that all of the white powder has dissolved before proceeding 
then make up the volume to a total of 50 mL by adding additional water. This solution can be 
stored at room temperature for >1 year. 
 
HPLC eluent (reverse-phase): Solvent A = water with 0.1% v/v TFA. Solvent B = MeOH with 






DFO-PEG3-ArN3 solution (~0.2 mM, pH 8.0 – 8.5): Prepare a stock solution by dissolving 0.75 
mg compound 1 (see Box 1) in 300 µL water. Check the pH by removing <1 µL aliquots and 
spotting on pH indictor strips. When necessary, adjust the pH first with small aliquots (typically 
<10 µL) of 1.0 M Na2CO3(aq.) and 0.1 M HCl(aq.) stock solutions. Dilute the ligand solution with 
water to give a clear colourless solution in a final volume of 350 µL (n(1) = 0.744 µmol, [1] = 2.13 
mM). Compounds 1 and 2 are water soluble. However, to facilitate dissolution of the aggregated 
particulates that form during lyophilisation, a compound can first be dissolved in DMSO (£10 µL; 
giving <3% v/v DMSO:water in the stock solution). Solutions of compounds 1 and 2 should be 
prepared fresh and can be stored at 4 oC for up to 1 week. The presence of <15% v/v DMSO in the 
reaction mixture does not interfere with the photochemical conjugation chemistry. ¨ CRITICAL 
DFO-ArN3 (3) has very low solubility in water. The compound dissolves at pH>11 but slowly 
precipitates as a white amorphous powder when the pH of the mixture is adjusted (pH 8.0 – 8.5) 
with 0.1 M HCl. Compound 3 is soluble in DMSO and if the protein or antibody remains stable, a 
higher ratio of DMSO:water up to 30% v/v can be used. Solutions of DFO-ArN3 (3) should be 
prepared fresh and used immediately.  
 
Neutralised [89Zr][Zr(C2O4)4]4– stock solution: Add an aliquot of the 89Zr-oxalate radioactivity 
from the commercial source (68.7 MBq, 70 µL in ~1.0 M aq. oxalic acid) to a glass vial containing 
water (200 µL). Neutralise and adjust the pH to slightly basic by the addition of aliquots of 
Na2CO3(aq.) (1.0 M stock solution; final pH ~8.3 – 8.5). ! CAUTION Acid neutralisation with 




Test the pH by removing an aliquot of the solution (<1 µL) and spotting on pH indicator strips 
(range 6.5 – 10.0). If the solution becomes too basic, the pH can be adjusted by using aliquots of 
0.1 M HCl(aq.). ¨ CRITICAL For optimum radiolabelling results, the neutralised solutions of 
[89Zr][Zr(C2O4)4]4– should be used within 24 h after preparation ensuring that the pH remains at 
the correct value before use.  
 
EQUIPMENT SETUP 
CRITICAL All instruments for measuring radioactivity should be calibrated and maintained in 
accordance with previously reported routine quality control procedures.25 
 
Radio-ITLC detector: Turn on the instrument and allow the detector to warm up for 15 min 
before use. Run a background scan using the same parameters as employed for the analytical 
samples to ensure that no radioactive contaminants are present on the scanner bed. 
 
HPLC method for analytical measurements: Turn on the electronic absorption and radioactivity 
detectors, and equilibrate the HPLC gel filtration column for 30 min before use. Run a blank 
sample injecting ~20 µL of water (reverse-phase) or PBS (SEC) to confirm that no impurities are 
present on the column or in the injection loop. For reverse-phase HPLC: use a gradient elution 
profile of 40% B (0 min) to 95% B (11 min) at a flow rate of 1.0 mL min-1.  For SEC gel filtration: 
use an isocratic elution profile with sterile PBS (1X, pH7.4) at a flow rate of 1.0 mL min-1. 
 
Gamma counter: Use an energy window of 480 – 558 keV for 89Zr (511 keV emission) and a 





Activimeter: Change the dose calibrator settings to measure 89Zr radioactivity. Measure a 
background sample to ensure that the dose calibrator is not contaminated before use. 
 
Geiger counter: Check the battery power and voltage. 
 
LEDs: Turn on the digital control box and allow the electronics to stabilise for 15 min at ambient 
temperature before use. 
 
PD-10 preconditioning: Before use, cut the plastic end (tip) to open 3 fresh PD-10 desalting 
columns (per radiolabelling experiment). Remove the cap and discard the storage solution. Rinse 
each column with 4´5 mL sterile 1X PBS. After preconditioning, add 1 mL PBS to the top of the 






Photoradiolabelling of mAbs with 89Zr and DFO-PEG3-ArN3 • TIMING 40 min 
! CAUTION Zirconium-89 is radioactive and emits positrons and high-energy gamma rays. This 
material should only be handled by trained personnel in approved radioactive facilities. Further 
details on the radioactivity are listed in the Materials section. 
¨ CRITICAL The temperature of all photochemical conjugation reactions is 23 ± 2 oC (ambient 
conditions). Although it is conceivable that slightly higher or lower temperatures can be used, 
reactions involving proteins should not exceed 37 oC to avoid thermal denaturation. 
1. Based on the known concentrations, calculate the volumes required of the stock solutions 
of protein, [89Zr][Zr(C2O4)4]4–, and DFO-PEG3-ArN3 (1). For example: 
• mAb aliquot: For a full-sized IgG1 antibody with a nominal molecular weight of 150,000 
Da, and a stock protein molality of 50 mg mL-1 ([protein] = 0.33 mM), an aliquot of ³45 µL 
would give a final protein concentration of ³0.1 mM (equivalent to a total n(protein) 
³15.0 nmol or 2.25 mg of protein). 
• DFO-PEG3-ArN3 (1) aliquot: For a stock concentration of 2.13 mM and desired chelate-to-
antibody ratio = 1.5, the [1] required (given by [protein] ´ initial chelate-to-protein ratio) 
= 0.1 mM ´ 1.5 = 0.15 mM. Volume required = 10.6 µL (equivalent to n(1) = 22.5 nmol). 
• [89Zr][Zr(C2O4)4]
4– aliquot: The molar activity of the neutralised 89Zr-stock solution can be 
determined experimentally by titration with a known amount of DFO. Alternatively, some 
manufacturers provide this information in the materials specification and data sheets. A 
conservative value for the molar activity of [89Zr][Zr(C2O4)4]
4-(aq.) is Am = 37.0 ± 0.12 MBq 
nmol-1 with activity concentrations in the range >2 GBq mL-1.15 At this value of Am, DFO-
PEG3-ArN3 can be radiolabelled with ~830 MBq of 




metal-to-ligand complex). For preclinical work, an activity of £74 MBq (£2 mCi) in 20 µL is 
typically used. This implies that more than a 10-fold excess of chelate is present in the 
initial reaction mixture ensuring quantitative and rapid 89Zr-radiolabelling of compound 1 
in <1 min under ambient conditions.26 
• Water balance: The amount of water required is equal to the final reaction volume minus 
the sum of the reagent aliquots. Here, V(H2O) = (150 µL – 75.6 µL) = 74.4 µL. 
¨ CRITICAL STEP The reaction mixture should contain a minimum protein concentration of 
0.1 mM. Conjugation yields decreased when protein concentrations below 0.1 mM were used.18 
¨ CRITICAL STEP The final reaction volume should be kept to a minimum (typically, Vtotal = 
150 µL). The initial chelate-to-protein molar ratio can be varied freely but should ideally be in the 
range 1:1 or 2:1. 
¨ CRITICAL STEP For radioactive work, it is important to ensure that enough chelate is present 
to complex the radionuclide. 
 
 
2. Pipette the required amount of water into the transparent glass vial equipped with a 
magnetic stir bar. 
3. Pipette the required volume of the photoactivatable reagent DFO-PEG3-ArN3 (1) into the 
glass vial and place the vessel on a magnetic stirring plate with rotation speed set at <1000 
rpm. 
4. Inside a lead shielded hood, pipette the desired amount of radioactivity (typically £74 
MBq) into the reaction. Measure the activity in the reaction vial by using the calibrated 




reaction (Ainitial / MBq; t = 0.0 min). With efficient mixing, the complexation of 89Zr4+ ions 
by the DFO-PEG3-ArN3 (1) chelate is generally complete in 1 – 2 minutes. 
! CAUTION All materials (including pipette tips, pH indicator paper and ITLC strips) that are 
used to handle, transfer or analyse radioactivity should be discarded after use in a labelled, plastic 
container, and stored behind a lead shield. 
5. Using a pipette, take an aliquot (<1 µL) of the reaction mixture from Step 4 and spot onto 
an ITLC strip (10 mm ´ 150 mm) at ~30 mm from the bottom of the strip. The position of 
the spot is defined as Rf = 0.0. The position of the solvent front is defined as Rf = 1.0 and 
is located at the top of the ITLC strip. Transfer the spotted ITLC strip into a TLC chamber 
containing the ITLC eluent. Develop the plate for ~2 – 3 minutes until the solvent front 
reaches the top of the ITLC strip. Remove the ITLC strip, seal in transparent adhesive tape 
(cellotape) to avoid radioactive contaminations, and record the chromatogram by using the 
radio-ITLC plate reader (see Anticipated Results Figure 6A for representative radio-ITLC 
data). ? TROUBLESHOOTING 
¨ CRITICAL STEP Ensure that the level of the ITLC eluent in the TLC chamber does not exceed 
the Rf = 0.0 threshold on the strip.  
¨ CRITICAL STEP Under these ITLC conditions, ‘free’ 89Zr4+ ions are rapidly coordinated by 
DTPA to give the [89Zr][Zr(DTPA)]– complex which migrates to the solvent front (Rf = 0.0). The 
desired species, [89Zr][Zr(DFO-PEG3-ArN3)]+ (also called 89Zr-1+) is retained at the baseline (Rf = 
0.0). The percentage of radiochemical conversion yield (RCC / %) to give 89Zr-1+ can be estimated 




= 0.0 – 0.1), and the total CPM recorded over the entire strip (Rf = 0.0 – 1.0) from Equation 1. 
Background subtraction can also be performed where necessary. 
RCC/% =	






× 100%  Equation 1 
6. Using a pipette, take another aliquot (<5 µL) of the reaction mixture from Step 4, transfer 
to a HPLC vial and (if necessary) dilute with 20 µL water. Analyse the formation of 89Zr-
1+ by reverse-phase HPLC. Co-elution of the radioactive 89Zr-1+ species with an 
authenticated sample of non-radioactive natZr-1+ can be used to confirm the identity of the 
radiolabelled compound. The procedure can be continued whilst the HPLC is acquiring 
data. ? TROUBLESHOOTING 
7. After confirming by radio-ITLC that 89Zr-1+ is formed in situ, pipette the required volume 
of protein stock solution into the reaction vial. 
8. Check the pH by removing an aliquot (<1 µL) and spotting a pH indictor strip (acceptable 
range pH 8.0 – 8.5). ? TROUBLESHOOTING 
9. Place the LED (365 nm or 395 nm) in position and secure with a retort stand and clamp. 
Irradiate the sample directly from above (see Figure 3). The digital controller can be used 
to define the irradiation time and tune the power (typical settings: 100% power for 15 min). 
¨ CRITICAL STEP The experimental geometry has a major impact on the flux of photons 
passing through the reaction mixture. Direct irradiation (with a correctly focused LED beam) of 
the open sample avoids potential issues with scattering, reflection and absorbance of the light by 
the glass. Specialised apparatus such as a mirrored photochemical light box can be used but the 
basic principle is that the focal point of the LED source should be located in the centre of the 




transmitted to the sample through the reaction vessel, the use of a quartz cuvette will minimise 
absorption and scattering. Standard actinometry measurements can be used to determine the power 
delivered into the sample.27 
 
10. After irradiation, remove the LED source. Using a pipette, take an aliquot (<1 µL) of the 
crude product from Step 9 and spot onto an ITLC strip. Develop and measure the ITLC 
strip as described in step 5. Radiolabelled protein is retained on the ITLC strip at Rf = 0.0 
(see Anticipated Results Figure 6A for representative radio-ITLC data). This analysis will 
confirm if the photochemical reaction has liberated any free 89Zr4+ ions due to 
decomposition of 89Zr-1+.  
11. Using a pipette, take two further aliquots (2´5 µL) of the crude mixture from Step 9. 
Transfer one aliquot into a HPLC vial and analyse the crude product by SEC-HPLC and 
(if necessary) dilute with water (20 – 50 µL) (see Anticipated Results Figure 6C for 
representative SEC-HPLC data).  
12. Transfer the second aliquot into an Eppendorf tube, dilute with 20 µL water, and retain for 
later analysis by manual analytical PD-10 size-exclusion chromatograph (see step 24). 
13. Measure the remaining activity in the reaction vial from Step 9 by using the activimeter 
and record the time (Acrude / MBq; crude activity). 
14. Remove the caps from a preconditioned PD-10 column, discard the PBS, and fix the 
column inside a lead shielded hood by using the retort stand and clamp. Place a labelled 
collection vial underneath the column (waste).  
15. From the remaining crude reaction mixture from Step 13, use a pipette to transfer an aliquot 




under gravity. Check the pipette tip by using the activimeter or Geiger Counter to confirm 
that the activity was transferred correctly. With a fresh pipette tip, add successive fractions 
of 1X PBS (1´380 µL, then 2´1,000 µL) to obtain a total loading volume of 2.5 mL. Collect 
the eluate in the waste vial, measure the activity by using the activimeter and record the 
time (waste activity). 
16. Measure the remaining activity in the crude reaction vial and record the time (Aresidual / 
MBq; residual activity).  
17. Place a sterile, labelled vial under the PD-10 column to collect the purified product. Elute 
the column with 1.6 mL (2 ´ 800 μL) (acceptable range: 1.5 – 2.0 mL) 1X PBS and collect 
the product fraction. The eluate contains the high-molecular weight fraction of purified 
protein but may also contain other species that have a nominal molecular weight >30,000 
Da. Continue to elute the PD-10 column with successive fractions of 1X PBS (2 ´ 1 mL) 
three times (fractions 2, 3, and 4).  
18. Measure the activity in the protein fraction and record the time (Apurified / MBq; purified 
product activity for fraction 1 at t = end of synthesis [EOS]). 
19. Measure the activity eluted fractions 2, 3, and 4, as well as the residual activity on the PD-
10 column. 
20. Calculate the decay-corrected radiochemical yield (RCY / %) of the isolated, radiolabelled 
protein in accordance with Equation 2. The ratio Vtotal / Vloaded corrects for the fact that only 
a 120 µL fraction of the reaction mixture was purified in step 15. 
¨ CRITICAL STEP All measured activities (measured in consistent units of either MBq or mCi) 





RCY	/	% = 	 +,1'-234, ∙ 5*+*,-5-+,./.. ,676,6.//   Equation 2 
? TROUBLESHOOTING 
21. Using a pipette, take three separate aliquots of the purified product from Step 18. Spot the 
first aliquot (<5 µL) spot onto an ITLC strip. Develop and measure the ITLC strip as 
described in step 5.  
22. Transfer the second aliquot (20 – 50 µL) into a HPLC vial and analyse the purified product 
by SEC-HPLC. ? TROUBLESHOOTING 
23. Transfer the third aliquot (20 – 50 µL) into an Eppendorf tube and retain for analysis by 
manual analytical PD-10 size-exclusion chromatograph in Steps 24-28. 
  PAUSE POINT The crude and purified aliquots that were retained for manual PD-10 SEC 
analysis should ideally be analysed immediately but can be stored at 4 oC for up 24 h. 
 
Manual PD-10 size-exclusion analysis • TIMING 25 min per sample 
24. Remove the caps from a preconditioned PD-10 column, discard the PBS, and fix the 
column inside a lead shielded hood by using the retort stand and clamp. Place a labelled 
collection vial underneath the column (waste). 
25. Using a pipette, transfer 20 µL of the retained crude reaction mixture from the Eppendorf 
tube (Step 12) on to the PD-10 column and allow the liquid to flow under gravity. With a 
fresh pipette tip, add successive fractions of 1X PBS (1 ´ 480 µL, then 2 ´ 1,000 µL) to 
obtain a total loading volume of 2.5 mL. Collect the eluate in the waste vial, measure the 




26. Elute the PD-10 column with (40 ´ 200 µL) fractions of 1X PBS collecting and capping 
each fraction in a separate gamma count vial. ? TROUBLESHOOTING 
¨ CRITICAL STEP Accuracy in collecting the 200 µL eluate fractions is crucial. Ensure that 
residual drops are collected from the end of the PD-10 column before changing the collection vial 
to prevent large errors in the measured PD-10 elution profiles. 
27. Repeat steps 24 – 26 using a fresh preconditioned PD-10 column for the aliquot of the 
purified product from Step 23.  
28. Measure the samples and appropriate blank tubes using a gamma counter. Data from the 
analytical PD-10 measurements (Steps 24-27) or the radioactive HPLC-SEC traces (Steps 11 and 
22) can be used to estimate the radiochemical purity of both the crude and purified samples. 
¨ CRITICAL STEP Each set of analytical PD-10 samples should be measured alongside a set of 
4 blank tubes to measure the background. The gamma count data for each sample should be decay-
corrected to the same time point before plotting the elution traces and performing other calculations 





CRITICAL: All stock solutions and equipment should be prepared in advance and are not 
included in the timing.  
Box 1, Synthesis and Characterisation of DFO-PEG3-ArN3 (1): 6 days 
Steps 1 – 23, Photoradiolabelling of mAbs with 89Zr and DFO-PEG3-ArN3: 40 min  




Step 28, Gamma counter analysis: timing depends on the counting time and time required for the 
robot to manoeuvre each tube or rack into position. A 30 second count of each tube would typically 






Troubleshooting advice is presented in Table 1. 
Table 1. Troubleshooting table. 
Step Problem Possible reasons Possible solution 
5 Radio-ITLC analysis 
indicates incomplete 
formation of 89Zr-1+ 
• Insufficient reaction time 
• Incorrect pH 
• Low molar activity of the [89Zr][Zr(C2O4)4]4– or the presence 
of chemical impurities such as Fe3+ or Ga3+ ions.  
 
• Leave the reaction for a further 5 min and repeat the ITLC 
analysis 
• Check and adjust the pH to 8.0 – 8.5. NOTE: 89Zr4+ metallation 
of DFO derivatives occurs efficiently at pH 5 – 10, however, 
one-pot photoradiochemistry requires slightly basic conditions. 
• Check the molar activity of the neutralised [89Zr][Zr(C2O4)4]4– 
• Discard solvents and prepare fresh buffer solutions using metal 
free reagents and Chelex® 100 resin treated distilled, deionised 
water to remove metal ion contaminants 
6 Reverse-phase radio-
HPLC analysis indicates 
incomplete formation of 
89Zr-1+ or the presence of 
free 89Zr4+ ions 
• Insufficient reaction time 
• Low molar activity of the [89Zr][Zr(C2O4)4]4– or the presence 
of chemical impurities such as Fe3+ or Ga3+ ions.  
 
• See Troubleshooting for Step 5 
• It is important to note that free 89Zr4+ ions will bind to protein 
non-specifically, however, the reaction conditions typically 
involve an excess of DFO chelate which is usually sufficient to 
complex all available 89Zr4+ ions and remove any activity that 




8 Incorrect pH • Impurities in the water or inaccurate pH of the stock solutions.  • Check and adjust the pH (8.0 – 8.5) of the stock solutions of 
DFO-PEG3-ArN3 and [89Zr][Zr(C2O4)4]4– by using aliquots of 
1 M Na2CO3(aq.) or 0.1 M HCl(aq.) and spotting on pH 
indicator strips. 
20 Low RCYs • Incorrect geometry of the photochemical apparatus 
• Incomplete photochemical activation of the ArN3 compound. 
• Check that the light is correctly focused on the reaction 
solution. 
• Perform a control experiment by omitting the protein 
component and replacing the volume with water. After 
irradiation of the 89Zr-1+ solution, remove an aliquot and 
analyse by reverse-phase HPLC. The peak associated with 
89Zr-1+ should be absent and the photolysis products are more 
polar and typically elute at shorter retention times.  
• See ANTICIPATED RESULTS for further comments on the 
observed RCYs from photoradiolabelling of proteins. 
22 SEC-HPLC analysis 
shows <90% 
radiochemical purity 
• PD-10 desalting columns are suboptimal for separating some 
small-molecule metal-ion complexes from the protein. 
Experience has shown that standard PD-10 columns are only 
efficient when the radiochemical purity of the crude mixture is 
>75%. For mixtures with higher fractions of radiolabelled 
small-molecule (<30,000 Da) components, separation 
efficiency decreased. 
• Consider using alternative gel filtration media such as 
polyacrylamide gels (Bio-Rad, P-4 gel, cat. no. 1504124; P-6 
gel, cat. no. 1504130) 
• Prepare a longer gel filtration column that will increase the 
separation between high- and low- molecular weight species. 
• Use centrifugal size-exclusion spin-filtration methods to 




• Using a concentrated sample of the product, repeat the PD-10 
purification (Steps 14 – 18)  




large errors or the 
activity peak for the 
protein fraction is not 
found in the 1.0 – 1.8 
mL window  
• PD-10 stops flowing 
or runs very slowly 
• Inaccurate loading of sample and water (Step 25) onto the PD-
10 column or inaccurate collection of the 200 µL fractions (e.g. 
loss of a drop during step 26) 
• Precipitates (from the protein or other components of the 
reaction mixture block the pores in the gel 
• Repeat the PD-10 analysis with a fresh column.  







As a representative example, details on the photoradiosynthesis of [89Zr]ZrDFO-PEG3-azepin-
onartuzumab are given in Figure 5. Results obtained from the radio-ITLC, analytical PD-10 
elution profiles and SEC-HPLC experiments for the synthesis of [89Zr]ZrDFO-PEG3-azepin-
onartuzumab are presented in Figure 6. Radio-ITLC data indicate the efficient radiolabelling of 
compound 1 with [89Zr][Zr(C2O4)4]4– and the facile separation of 89Zr-1+ (green trace) from the 
control [89Zr][Zr(DTPA)]– (black trace). Under the radio-ITLC conditions employed, 89Zr-
radiolabelled proteins are retained at the baseline (Rf = 0.0). Analytical PD-10 elution profiles from 
the crude (red) and purified (blue) protein mixtures can be used to estimate the radiochemical 
purity. The marker set at 1.6 mL indicates the cut-off used to isolate the radiolabelled 
[89Zr]ZrDFO-PEG3-azepin-onartuzumab during preparative PD-10 chromatography (Step 17). 
Size-exclusion HPLC analysis is a more reliable way to estimate the radiochemical purity of the 
final product. Co-elution of the radiolabelled protein with the UV trace (purple) from MetMAbTM 
confirms the identity of the product as an 89Zr-mAb. In addition, SEC-HPLC can reveal the 
presence of aggregated protein (*) or small-molecule by-products from the photolysis of 89Zr-1+ 
(D). Experiments found that the molar activity of 89Zr-mAbs produced by photoradiosynthesis can 
be >13 MBq nmol-1.15,18 We note that this number is mostly limited by the fact that our facility is 
only equipped to handle small amounts of 89Zr radioactivity in manual syntheses. Higher molar 
activities are likely to be achieved by facilities that can perform radiolabelling reactions with 
higher initial amounts of radioactivity. Cellular binding assays also confirmed that 
photoradiolabelled mAbs remain immunoreactive.15,16,18,20 PET imaging studies in athymic nude 




that [89Zr]ZrDFO-PEG3-azepin-onartuzumab is a viable radiotracer for measuring the expression 
of the human hepatocyte growth-factor receptor (c-MET) (Figure 7).20 
 
Optimisation studies revealed that, alongside standardisation of the experimental 
geometry, changes in the protein concentration have a major impact on the isolated RCYs (Table 
2). Initial experiments with 89Zr-3+ encountered problems due to the limited solubility of the DFO-
ArN3 (3) compound in aqueous conditions.15 Synthesis of the water-soluble chelates 1 and 2, 
improved the reliability and RCYs for 89Zr-radiolabelling of several proteins.20 Decay-corrected 
RCYs of the isolated 89Zr-photoradiolabelled proteins still show dependence on the nature of the 
protein and on the composition of the formulation buffer. In our experiments, photoactivatable 
[89Zr]ZrDFO complexes derived from compound 1, 2, and 3, have (so far) resulted in the highest 
RCYs of conjugated protein. The use of other photoactivatable metal binding chelates (including 
well-known polyazamacrocycles, HBED-CC-ArN3, and DTPA-ArN3) with 68Ga3+ or 111In3+ ions 
gave radiolabelled protein but with lower RCYs.13,14,16,17  
For photochemical conjugation reactions using ArN3, experimental evidence indicated that 
radiochemical conversions to the labelled protein decrease below pH 7 and above pH 9.1.13 At 
neutral or acidic pH, free primary amines on the protein are likely to be fully protonated (pKa 
[lysine e-NH2] = 10.5), and are not available to attack the ketenimine electrophile that is produced 
after light-induced activation of the ArN3 group. At pH >9, quenching by hydroxide can become 
rate limiting. Further experimental and computation studies are underway to improve RCYs, to 
develop photoactivatable fluorophores21 and cytotoxic drugs, and to explore the chemical scope 
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FIGURES AND FIGURE LEGENDS 
 
 
Figure 1. The general concept of light-induced activation and protein functionalisation. 
 
Figure 2. Chemical structures of three photoactivatable DFO derivatives. 
The structures of compounds 1 – 3 are shown. Note, the water-soluble version, DFO-PEG3-ArN3 
(1) incorporates a discrete tris-polyethylene glycol (PEG3) spacer between the metal ion binding 
moiety and the ArN3 group. (Adapted from Guillou et al., Chem. Eur. J., 26, 7185-7189 (2020)).20 
 
Figure 3. Photochemical apparatus and experimental setup.  
A simple experimental setup for direct irradiation of a sample in an open vial is shown. More 
sophisticated experimental apparatus (such as light boxes) can be used for performing 
photochemical reactions. (Adapted from Patra et al., Angew. Chemie Int. Ed., 58, 1928–1933 
(2019). DOI: 10.1002/anie.201813287).13 
 
Figure 4. Emission spectra and beam shape. 
Emission spectra of two LED sources with peak emissions at 365 nm (blue) and 395 nm (black). 
(Inset) Photograph of the emission geometry and focal point located ~1 cm from the lens. (Adapted 
from Patra et al., Angew. Chemie Int. Ed., 58, 1928–1933 (2019). 
DOI: 10.1002/anie.201813287).13 
 





The reaction starts from fully formulated MetMAbTM, DFO-PEG3-ArN3 (1), and [89Zr(C2O4)4]4– 
(89Zr-oxalate). 
 
Figure 6. Analytical data on the synthesis and characterisation of [89Zr]ZrDFO-PEG3-azepin-
onartuzumab.  
Representative analytical data from the photoradiosynthesis of [89Zr]ZrDFO-PEG3-azepin-
onartuzumab starting from DFO-PEG3-ArN3 (1), [89Zr][Zr(C2O4)4]4–, and formulated MetMAbTM 
are shown. a Radio-ITLC chromatograms, b analytical PD-10 elution profiles, and c SEC-HPLC 
chromatograms of [89Zr][Zr(DTPA)]– (black), 89Zr-1+ (green), [89Zr]ZrDFO-PEG3-azepin-
onartuzumab crude (red) and purified products (blue) and the UV trace of MetMAbTM (purple) 
showing co-elution with the radiolabelled protein peak. * peak associated with a minor protein 
aggregate fraction; D broad peak associated with radiolabelled small-molecule biproducts from the 
photolysis of 89Zr-1+. (Adapted from Guillou et al., Chem. Eur. J., 26, 7185-7189 (2020)).20 
 
Figure 7. Representative PET images using [89Zr]ZrDFO-PEG3-azepin-onartuzumab.  
Coronal and axial PET images taken through the centre of the tumours showing the spatial 
distribution of [89Zr]ZrDFO-PEG3-azepin-onartuzumab over time after intravenous administration 
in mice bearing MKN-45 tumours. T = tumour, H = heart, L = liver, Sp = spleen. (Adapted from 
Guillou et al., Chem. Eur. J., 26, 7185-7189 (2020) – this reference contains full experimental 
details for the PET image acquisition and data analysis).20 PET imaging was conducted in 
accordance with an animal experimentation protocol approved by the Zurich Canton Veterinary 






Table 2. Variations in radiochemical yields for photoradiolabelling of three different proteins with 
89Zr-1+, 89Zr-2+ or 89Zr-3+.15,18,20 





Irradiation time and 
wavelength [l / nm] 
Decay-corrected radiochemical 
yield (RCY) / % ± 1 standard 
deviation for n replicates 
89Zr-1+ HSAb, 175 µM 1.2 15 min, 395 nm 72.9±1.9% (n = 3) 
89Zr-1+ HSA, 175 µM 1.2 15 min, 365 nm 70.7±2.3% (n = 3) 
89Zr-1+ MetMAbTM, 141 µM 1.5 15 min, 395 nm 64.5±6.7% (n = 3) 
89Zr-1+ HerceptinTM, 77 µM 2.8 15 min, 395 nm 58.3±3.4% (n = 3) 
89Zr-2+ HSA, 175 µM 1.2 15 min, 395 nm 59.6±3.6% (n = 3) 
89Zr-3+ Trastuzumab, 51 µM  28.9 10 min, 365 nm 67 – 88% (n = 2) 








10 min, 365 nm  
41.2 ± 10.6% (n = 3) 
33.7 ± 5.8% (n = 3) 
34.9 ± 10.4% (n = 3) 
a HerceptinTM and MetMAbTM indicate that the formulated protein stocks were used directly 
without pre-purification of the protein. Trastuzumab indicates that the purified protein sample was 
used in the photoradiolabelling reactions. 
b HSA = human serum albumin 
 
